E pilEpsy is estimated to affect between 2.5 and 3 million people in the United States, with a prevalence of 5 to 10 persons per 1000. 32 It has been shown that about 47% of patients with a new diagnosis of focal-onset epilepsy are successfully treated with the first antiepileptic drug (AED) prescribed. 19 Therapeutic failure of 2 AEDs is defined as drug-resistant epilepsy. 2,5 Approximately 20% to 40% of patients with epilepsy are likely to have drug-resistant epilepsy. 4, 26, 27 Patients with a unilateral lesion on high-resolution MRI that is concordant with the aBBreViatiOnS aECoG = acute electrocorticography; AED = antiepileptic drug; ECoG = chronic electrocorticography; EEG = electroencephalography; ETLE = extratemporal epilepsy; IOZ = ictal onset zone; SISCOM = subtraction ictal SPECT coregistered to MRI; SPGR = spoiled gradient recalled; TLE = temporal lobe epilepsy.
electroencephalography (EEG) findings and seizure semiology have the best outcomes after resection. 13, 31, 34 Unfortunately, 20% to 30% of temporal lobe epilepsy (TLE) patients and 20% to 50% of extratemporal lobe epilepsy (ETLE) patients demonstrate the absence of an underlying lesion on high-resolution MRI. 6, 16, 18 Resective targeting of the ictal onset zone (IOZ) is most challenging in patients with nonlesional MRI and focal-onset epilepsy. Previous postresection outcome studies report seizure freedom to be the greatest after resection in lesional TLE patients, where 75% to 85% of patients achieve Engel Class I after 2 years of follow-up (Engel classification: Class I, seizure free; Class II, rare disabling seizures; Class III, worthwhile improvement; and Class IV no worthwhile improvement). 3, 9 Patients with lesional ETLE have seizure-free rates (Engel Class I) of around 60% (at 1-year follow-up). 31 In contrast, patients with nonlesional TLE demonstrate outcomes with seizure-free rates (Engel Class I) ranging from 41% to 65% (at 2-year follow-up). 1, 14, 24, 30 Patients with nonlesional ETLE exhibit the lowest seizure-free outcomes, ranging from 24% to 42% (at 2-year follow-up). 8, 20, 23 A better understanding is necessary to evolve our approach toward recognizing the IOZ as a critical node in a larger epileptogenic network in order to achieve better seizure-free rates, particularly in nonlesional focal-onset epilepsy.
In the present study, we retrospectively analyzed the clinical history profiles including duration of epilepsy, video EEG (noninvasive and invasive) and MRI findings, subtraction ictal SPECT coregistered to MRI (SISCOM) data, seizure semiology, sites and sizes of resection, pathological findings, and postsurgical seizure outcomes in a cohort of patients with lesional and nonlesional ETLE and TLE. The aim of our study was to assess the positive predictive value of resecting SISCOM regions of transient hyperperfusion that were associated with the IOZ. Also, the long-term postsurgical outcomes in patients with both MRI-positive and MRI-negative ETLE and TLE were compared.
methods patients
A total of 567 presurgical SPECT studies (243 patients) were performed at our center between 2002 and 2013. Our study included a cohort of 44 patients from this presurgical group who underwent resective epilepsy surgery. The mean age of the patients in our cohort was 29 years (range 11-57 years; SEM 1.8) ( Table 1) . Patients underwent follow-up for a mean of 5 years (range 2-10 years). All patients in our cohort were assessed using chronic intracranial electrode electrocorticography (ECoG) monitoring and/or acute intraoperative electrocorticography (aECoG). The placement of the electrodes for invasive monitoring was determined during an epilepsy surgery management conference at our institution. Multiple factors were analyzed to generate the hypothesis for intracranial electrode placement and targeting the IOZ. To facilitate localization of the IOZ, we employed seizure semiology, MRI, chronic noninvasive scalp video-EEG monitoring, magnetoencephalography, SISCOM, positron emission tomography, and neurocognitive testing ( Table 2) .
We included patients based on the following inclusion criteria: 1) diagnosis of drug-resistant, focal-onset epilepsy based on presurgical evaluation that included SIS-COM; and 2) resective epilepsy surgery performed with a postoperative follow-up of ≥ 24 months (mean followup 5 years). The predominant reasons for exclusion from the study were 1) patient underwent less than 24 months of follow-up (except patients who remained as Engel Class IV [no worthwhile improvement]), or 2) no interictal SPECT was acquired. Forty-four patients met all of the inclusion criteria and were analyzed in this study. One ETLE patient in the study had undergone a previous resection prior to a second resection. In 25 (61%) patients, postresection MRI was performed. Preresection subtraction ictal SPECT was coregistered to the patient's postresection MRI study, which was acquired at least 12 months postoperatively. This technique accounted for brain shift following resection. This strategy was used to determine the regions of transient hyperperfusion in comparison with the extent of resection.
high-resolution mri
High-resolution, gapless, pre-and postgadolinium, volumetric, spoiled gradient recall (SPGR) MR images of the brain were obtained for each patient. The MRI examination was performed using a 1.5-or 3-T scanner (Siemens). A gapless, SPGR, T1-weighted sequence data set for each patient was acquired at a slice thickness of 1.0 or 1.6 mm.
noninvasive Video-eeg monitoring
Chronic, noninvasive video-EEG monitoring was performed in each patient using the International 10-20 system for electrode placement, including anterior temporal and sphenoidal electrodes if appropriate. AEDs were lowered during chronic monitoring, all patients were electrographically monitored to record the typical seizures, and video recordings were generated to monitor semiology.
SiScOm
SPECT was performed on each patient during video-EEG monitoring using Ceretec ( 99m Tc-HMPAO) or Neurolite ( 99m Tc-ECD) at a dose of 24 to 26 mCi (adjusted for body weight). The radiotracer was injected for the ictal SPECT studies with an autoinjector (MedRad) used by a specially trained nuclear medicine technologist (V.P.) while at the patient's bedside during seizure onset. The technologist was trained to inject at the clinical and/or electroencephalographic seizure onset, whichever came first. The seizure-onset and ending times were always noted. Also, the time from the beginning of injection up to the complete depression of the syringe plunger was noted. We retrospectively calculated the time of the radiotracer injection following seizure onset by reviewing the video-EEG recordings for all patients. To avoid injection during the postictal state, a minimum of 15 seconds was required between the end of radiotracer injection and the end of the seizures, as described above. Baseline SPECT was obtained by performing an interictal injection after a seizure-free period of ≥ 24 hours. Brain SPECT scans were obtained within 2 hours after injection using a Siemens E.CAM Dual-Detector gamma camera with BiOCORE fan beam collimators. Thirty-two views per detector (total 64) were acquired using 80,000 counts per view, circular orbit, and "step and shoot" mode. Images were reconstructed by Syngo Siemens AG software using a 128 × 128 matrix with a Butterworth filter. DICOM isotropic datasets with a voxel size of 3.9 mm were created and transferred to Analyze software (An-alyzeDirect). Analyze version 10 was used to perform ictal and interictal SPECT thresholding, normalization, subtraction, and coregistration to the patient's MRI study. Finally, the brain was segmented from the extracerebral structures, as identified on the patient's volumetric MRI study. The cerebral surface of the binary ictal SPECT was matched to the cerebral surface of the binary MRI. The resulting registered transformation matrix was then applied to the subtraction SPECT data set in order to coregister it to the processed MRI study. Complete, gapless, SISCOM image sets were presented to a blinded, board-certified epilepsy neurologist (M.A.R.) who determined the SISCOM region of transient hyperperfusion for each patient in this study.
invasive recording
The ECoG electrode placement plan (subdural grid electrodes and/or depth electrodes) was confirmed using head CT. In 41 patients, chronic bedside ECoG monitoring was performed to investigate the clinical electrocerebral IOZ based on the patient's stereotypic seizure. For 3 patients, aECoG monitoring alone provided enough information to establish the IOZ.
pathology
A pathological diagnosis of the resected specimens, such as gliosis, focal cortical dysplasia, heterotopias, tumor, or mesial temporal sclerosis, was determined for 38 of 44 (86%) patients ( Table 2) .
postoperative Seizure Outcomes
Postoperative outcomes were determined by following 38 patients for a period greater than 24 months (mean follow-up 5 years; range 2-10 years) after resection. We classified the postresection outcomes into 4 classes and subclasses according to Engel's classification. 11 At the time * Engel classification: Ia, completely seizure free since surgery; Ib, nondisabling, simple partial seizures only after surgery; Ic, some disabling seizures after surgery, but free of disabling seizures for at least 2 years; Id, generalized convulsions with AED discontinuation only; IIa, initially free of disabling seizures, but has rare seizures now; IIIa, worthwhile seizure reduction; IIIb, prolonged, seizure-free intervals amounting to greater than half of the follow-up period, but for less than 2 years; IVa, significant seizure reduction; IVb, no appreciable change; IVc, seizures worse after surgery. » CONTINUED FROM PAGE 1569 of our analysis, 5 patients in our study received a followup period of 17 to 18 months. However, these patients remained classified as Engel Class IV. One of the patients in our study was observed for only 12 months. However, this patient remained in Engel Class IVc (no worthwhile improvement, worsening of seizures after surgery).
postresection mri
We obtained postresection MRIs for 34 of 44 (77%) patients. We coregistered the preresection SISCOM on postresection MRI in order to evaluate the extent of resection of the identified SISCOM region of hyperperfusion. Using traditional SISCOM processing with Analyze, we could not achieve accurate registration of the preresection SISCOM signals on the postresection MRI studies for all patients. Postresection MRI findings were considerably different from preresection MRI findings due to the creation of new cortical boundaries, particularly in the area of resection. In addition, the craniotomy flap altered the skull shape in some patients. Consequently, clean object extraction could not be achieved in several postresection MRI data sets, resulting in poor registration. To solve this problem, we employed a different postprocessing method. We performed 3-dimensional voxel registration using Analyze between the original fused preresection SISCOM, which was used as the base, and the postresection MRI, which was used as the match. We first performed manual registration to achieve similar alignment in all 3 planes (transverse, coronal, and sagittal). We then performed autoregistration using the register tab in the 3-dimensional voxel registration window in Analyze. This process perfectly aligned the two 3-dimensional objects, so that each voxel in the new fused image represented the same voxel of the base (preresection SISCOM) and match (postresection MRI).
The intensities of the base and match were modified as follows. The minimum intensity of the base image was increased in order to make the preresection MRI disappear and reduce the maximum of the base in order to improve the SPECT signal. This technique prevented the preresection brain tissue boundary from filling the resection site. Thus, the fused image demonstrated the properties of the SPECT signal of the base, but not the MRI properties of the base. Lastly, we reduced the maximum intensity of the match to intensify the postresection MRI. This technique enabled us to better visualize the resection site. This process resulted in the accurate registration of the preresection, SISCOM hyperperfusion signals over the postresection MRI, and, at the same time, improved the intensity of the resection site.
analysis and Statistics
Concordance was determined between SISCOM localization and ECoG on the basis of an overlapping IOZ and called "concordance with the ECoG." Concordance was also determined between SISCOM localization and the resection site, or "concordance with the resection site." Two different concordance types are designated since resection usually involves a larger area than the IOZ, as determined by ECoG. Strict concordance criteria were used, where > 90% of the resected area must overlap with the SISCOM signal to be considered concordant. Concor-dance was determined by a blinded, board-certified epilepsy neurologist (M.A.R.).
We coregistered preresection and subtracted ictal SPECT on postresection MRI to determine if the SISCOM signal was completely or partially removed. We determined if complete or partial resection impacted postoperative outcomes.
Our cohort of 44 patients underwent resective epilepsy surgery. All patients underwent follow-up for at least 2 years (mean follow-up 5.0 years; range 2-10 years). Five patients only received 17 to 18 months of follow-up at the time of our analysis, but these patients demonstrated Engel Class IV outcomes. One of the patients completed a follow-up of only 12 months, but achieved Engel Class IVc. The mean radiotracer injection time for all patients was 45 seconds (SEM 11.4) after electrocerebral seizure onset. In our cohort, all SPECT studies were performed during the patient's stereotypic seizures, as measured electrographically or clinically.
results ecog monitoring
ECoG concordant tissue was completely resected from all 44 patients. Of these 44 patients, 24 of 44 (55%) became seizure free (Engel Class I) after at least 2 years of follow-up after resection.
SiScOm concordance
SISCOM was concordant with ECoG and the resection site in 32 of 44 (73%) patients, and 20 of these 32 (63%) became seizure free (Engel Class I after > 2 years followup). Of these 32 patients, 19 of 32 (59%) were ETLE and 13 of 32 (41%) were TLE (Fig. 1) . The mean injection time was 46 seconds in the SISCOM ECoG concordant group (SEM 14.5).
SiScOm concordant etle group
In 19 ETLE patients with concordant SISCOM and ECoG results, ECoG delineated the epileptogenic source or focus, which was completely resected in all patients; 11 of 19 patients (58%) became seizure free (Engel Class I) ( Table 3) .
Among these 19 ETLE patients, 8 patients exhibited a lesion on MRI (focal cortical dysplasia, tumor, double cortex, or encephalomalacia). Only 6 of these 8 patients exhibited an MRI lesion and SISCOM focus that were both concordant with the ECoG results; only 3 of these 6 patients (50%) became seizure free (Engel Class I) ( Table 3) .
Also, among these 19 ETLE patients, 11 patients were MRI negative for lesions. For these patients, SISCOM facilitated the placement of the intracranial electrodes; 7 (64%) patients became seizure free (Engel Class I) ( Table 3) .
SiScOm concordant tle group
In the 13 TLE patients with concordant SISCOM and ECoG results, the indicated ECoG focus was completely resected; 9 of 13 patients (69%) became seizure free (Engel Class I) ( Table 3) .
Among these 13 TLE patients, 11 patients had a lesion (mesial temporal sclerosis, focal cortical dysplasia, or tumor) on MRI. Only 8 of these 11 patients demonstrated an MRI lesion and SISCOM focus that were both concordant with the ECoG results; 7 of these 8 patients (88%) became seizure free (Engel Class I) ( Table 3) . Also, among these 13 TLE patients, 2 patients were MRI negative. For these patients, SISCOM guided the placement of the intracranial electrodes; 1 (50%) patient became seizure free (Engel Class I) ( Table 3) .
nonconcordant group
SISCOM was nonconcordant with ECoG but overlapped with the resection site in only 1 of 44 patients. This patient was diagnosed with nonlesional ETLE but did not exhibit a lesion on MRI. This patient demonstrated a worse outcome after resection and achieved Engel Class IV (> 2 years of follow-up, Fig. 1 ).
SISCOM was nonconcordant with ECoG and nonoverlapping with the resection site in 11 of 44 patients ( Fig. (Table 4 ).
For the SISCOM nonconcordant group, the average injection time was 37 seconds (SEM 11.3).
resection of SiScOm Focus
We coregistered the preresection subtraction ictal SPECT to each patient's postresection MRI in order to determine if the SISCOM signal(s) used to guide the placement of the intracranial electrodes preresection was completely, partially, or not resected. A 10% shifting of the adjacent brain postresection was assumed in the postresection MRI coregistrations. Postresection MRI studies were completed in 35 of 44 (80%) patients.
Complete resection of the SISCOM signal was found in 7 of 34 patients (21%). Of these 7 patients, 5 patients (72%) were seizure free (Engel Class I). Partial resection of the SISCOM signal was found in 16 of 34 patients (47%); 10 of these 16 patients (63%) were seizure free (Engel Class I) after more than 24 months of follow-up ( Table 5 ).
The SISCOM signal was not resected in 11 of 34 (32%) patients. Four of these 11 patients (36%) were seizure free (Engel Class I) after more than 24 months of follow-up.
pathology
The pathological findings (gliosis and focal cortical dysplasia) (p = 0.1007) were not significantly correlated with the outcomes of epilepsy surgery ( Table 2) .
discussion
The success of epilepsy surgery depends on the accurate anatomical localization of the IOZ, which is indispensable to contributing to favorable outcomes. The IOZ is a com-ponent of the ictal circuitry that is critically involved in the initiation of seizure. Scalp EEG and semiology are often not sensitive enough to accurately delineate the IOZ in rapidly propagating seizures. Consequently, the development of novel neuroimaging approaches is required to facilitate visualizing the IOZ, particularly in patients with ETLE. SISCOM can help identify the IOZ, though its limitations as an indirect measure of increased metabolic demand in the nearby epileptogenic cortex must be kept in mind. The probability of seizure freedom in our cohort is highest for lesions identified on MRI. Patients with MRI findings showing lesions in 1 temporal lobe that are concordant with ipsilateral ictal activity on EEG have the highest rate of seizure freedom after resective epilepsy surgery. 13, 31 In our cohort, 7 patients demonstrated underlying lesions in 1 temporal lobe (predominantly mesial temporal sclerosis), and a concordant abnormality on scalp EEG was noted in 6 of these patients; all 7 of 7 (100%) patients achieved Engel Class I with longer than 3 years follow-up (mean follow-up 4.9 years). SISCOM was concordant with the resection site in 6 of 8 (75%) of these patients.
It has been previously shown that the probability of seizure freedom (Engel Class I) at the 12-month follow-up after surgery is 2.7 times higher in TLE patients with MRI lesions in comparison with TLE patients without MRI lesions. 31 Moreover, the probability of seizure freedom (Engel Class I) at the 12-month follow-up after surgery is 2.9 times higher in ETLE patients with MRI lesions in comparison with ETLE patients without MRI lesions. 31 SISCOM impacted our postresection outcomes in the nonlesional ETLE and TLE patient groups. Also, the complete or partial resection of the SISCOM region of transient hyperperfusion plays a role in seizure freedom; 5 of 7 (72%) patients were seizure free after complete resection of SISCOM hyperperfusion-related signaling, and 10 of 16 (63%) patients were seizure free after the partial resection of similar SISCOM signals. In our study, 6 patients exhibited SISCOM signal foci localized with the resection site; these patients demonstrated poor surgical outcomes (Engel Class IV), and at least 1 SISCOM region not overlapping with the resection site ( Fig. 2) . Concordance between SISCOM with ECoG had a sensitivity of 72.7%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 14.3%. Improved outcomes were seen with earlier surgery for intractable frontal lobe epilepsy. 28 In our study, the mean duration of frontal lobe epilepsy was 19.17 years. When the duration of frontal lobe epilepsy was < 5 years, 75% became seizure free (n = 4; 3 MRI lesion-positive and 1 MRI lesion-negative patients) (Engel Class I, mean year of follow-up postresection 7.7 years, range 6-10 years, SD 2.08). However, when the duration of frontal lobe epilepsy was ≥ 5 years, 59% became seizure free (n = 17; 7 MRI lesion-positive and 10 MRI lesion-negative patients) (Engel Class I, mean year of follow up postresection 7.3 years, range 3-11, SD 2.8).
According to previously published success rates for partial frontal lobectomy, favorable outcomes (Engel Class I) range from 15% to 35% in these trials. 7, 12, 20, 25, 29, 36 The only variable that was significantly associated with a favorable surgical outcome was a focal MRI abnormality in frontal lobe epilepsy. 13 Elsharkawy et al. published a retrospective study investigating 97 patients with lesional frontal lobe epilepsy who underwent resection. 10 This study reported the seizure freedom rates (Engel Class I) to be 54.6% at 6 months, 49.5% at 2 years, 47% at 5 years, and 41.9% at 10 years. 10 In yet another series, 41% of nonlesional TLE patients showed excellent outcomes versus 72% when an MRI abnormality was present. 21 Previous studies that report favorable (Engel Class I) outcomes investigated patients with frontal lobe tumors or focal cortical dysplasias. 36 Other factors that predict seizure recurrence include incomplete resection of the epileptogenic lesion, 7, 10, 17, 33, 36 predominantly generalized or poorly localized ictal EEG patterns on surface EEG, 10, 17, 35 the lack of a subdural grid evaluation, 10,17 acute postresection seizures, 6 postoperative persistence of prolonged auras, 10,17 history of febrile seizures, 21 and the lack of a distinct MRI lesion. 7, 10, 17, 22, 33, 35 The SISCOM results in our study patients influenced the planning of intracranial electrode placement. Therefore, our ECoG results were, in part, influenced by our SISCOM data. Also, all patients in our cohort underwent SISCOM as part of the presurgical evaluation. Therefore, potential selection bias toward patients with more localizable IOZ has to be regarded, and consequently resulted in more favorable postresection outcomes.
conclusions
The goal of resective epilepsy surgery is long-term seizure freedom (Engel Class I or II). Seizure outcomes are time dependent and dynamic. All prognostic factors converge into one central theme: an epileptogenic zone that is well visualized and also electrically and semiologically restricted, in that its extent offers the best chance of seizure freedom when resected completely. However, SISCOM provides an indirect measure of localizing the IOZ, which often coincides with the critical nodes within the epileptogenic network.
These data confirm previous studies that demonstrate the utility of SISCOM by improving the outcomes of drugresistant, focal-onset epilepsy in both ETLE and TLE patients. Concordance between SISCOM and ECoG and/or aECoG in this refractory epilepsy cohort provides useful additional information for predicting postresection outcomes. In addition, the limitations in SPECT scanner technology may contribute to the sensitivity of SISCOM for identifying the maximal extent of the critical nodes or the generators of the epileptogenic circuit. The predominant limitation of conventional SPECT technology is the voxel resolution, which is limited to 8 to 12 mm with inadequate attenuation correction. The limitations of the spatial resolution of SPECT are related to using only 2-and 3-head photon detectors to record low-energy single-photon events.
Next-generation SPECT scanner systems with significantly improved resolution and complementary postprocessing techniques will facilitate identifying a greater extent of the critical nodes in an epileptogenic network. 16 Such technology will augment guiding ECoG electrode placement in potentially extensive epileptogenic networks.
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